The toxicity of troglitazone, roziglitazone and vitamin e in human hep g2 hepatoma cells

A.J. Ball, J.N.A. Tettey, M.H. Grant

Research output: Contribution to journalConference Contribution

Abstract

Troglitazone (TGZ), a member of the thiazolidinedione class of drugs used to treat type-II diabetes, has been associated with hepatotoxicity (Biswas et al., 2001). TGZ differs structurally from the newer non-hepatotoxic glitazone, rosiglitazone (RGZ), in that it contains the chromanol moiety of Vitamin E (Vit E). This study compares
the toxicity of TGZ, RGZ and Vit E in human HepG2 cells
Original languageEnglish
Pages (from-to)250-251
Number of pages2
JournalToxicology
Volume194
Issue number3
DOIs
Publication statusPublished - 2004

Keywords

  • troglitazone
  • roziglitazone
  • toxiciology

Fingerprint Dive into the research topics of 'The toxicity of troglitazone, roziglitazone and vitamin e in human hep g2 hepatoma cells'. Together they form a unique fingerprint.

  • Cite this